rare

MG 3 receives four stars but suffers rare and serious seat failure in Euro NCAP crash test

LEUVEN, BELGIUM – For decades, MG’s catchy slogan was ‘Safety Fast’ as the British marque traded on sporty cars that…

2 weeks ago

Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025

September 09, 2025 11:00 ET  | Source: Chiesi Global Rare Diseases Results presented focus on clinical insights on Fabry disease…

2 weeks ago

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…

3 weeks ago

Limited Drop, Maximum Flex: Cleveland Golf and SWAG Partner for RTZ Wedge Collaboration

HUNTINGTON BEACH, Calif., Aug. 28, 2025 – When pure contact meets unfiltered creativity, something special happens. Introducing the Cleveland Golf…

4 weeks ago

London musician with brain tumour inspires Brighton triathlon fundraiser

Tuesday 26 August, 2025 A talented musician from London, who died from a rare brain tumour in January this year…

4 weeks ago

A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care

RIYADH, Saudi Arabia, Aug. 24, 2025 (GLOBE NEWSWIRE) -- In a rare example of a lifelong bond between a patient…

1 month ago

UltraLuxe Singapore 2025 Showcases The Collectable And Investible In Niche Luxury Through Immersive And Social Experiences

SINGAPORE, Aug. 20, 2025 /PRNewswire/ -- From jewellery and fashion to art, wellness, gastronomy, and lifestyle, UltraLuxe returns for its fourth…

1 month ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Celebrates Indian Independence Day by Honoring the US-India Innovation PartnershipCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company…

1 month ago

FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…

2 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical…

2 months ago